Evidence map›Paper›PMID 38264218›Full record

ArticleDiabetology international2024

Third Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on diabetes and cancer: summary of the results of a questionnaire survey of oncologists and diabetologists-secondary publication.

Atsushi Goto, Ken Ohashi, Mitsuhiko Noda, Hiroshi Noto, Kohjiro Ueki, Manami Inoue, Rimei Nishimura, Shin Takahashi, Tatsuya Ioka, Masanobu Oshima and 10 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Atsushi GotoDepartment of Public Health, School of Medicine, Yokohama City University, Yokohama, Japan.
Ken OhashiDepartment of General Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
Mitsuhiko NodaDepartment of Diabetes, Metabolism and Endocrinology, Ichikawa Hospital, International University of Health and Welfare, Ichikawa, Japan.
Hiroshi NotoDivision of Endocrinology and Metabolism, St. Luke's International Hospital, Tokyo, Japan.
Kohjiro UekiDepartment of Molecular Diabetic Medicine, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan.
Manami InoueInstitute for Cancer Control, National Cancer Center, Tokyo, Japan.
Rimei NishimuraDivision of Diabetes, Department of Internal Medicine, Metabolism and Endocrinology, Jikei University School of Medicine, Tokyo, Japan.
Shin TakahashiChemotherapy Center, Sendai Kousei Hospital, Sendai, Japan.
Tatsuya IokaDepartment of Oncology Center, Yamaguchi University Hospital, Ube, Japan.
Masanobu OshimaDivision of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Kazutoshi FujibayashiGeneral Practice, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Akihito TsujiDepartment of Clinical Oncology Faculty of Medicine, Kagawa University, Takamatsu, Japan.
Makoto KodairaDivision of Internal Medicine and Medical Oncology, Kodaira Hospital, Saitama, Japan.
Akiko TamakoshiFaculty of Medicine, Hokkaido University, Sapporo, Japan.
Koshi MimoriDepartment of Surgery, Beppu Hospital, Kyushu University, Beppu, Japan.
Yuko TanabeDepartment of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Eiji HaraDepartment of Molecular Microbiology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
Keitaro MatsuoDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center, Nagoya, Japan.
Yoshinori MurakamiDivision of Molecular Pathology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hirotaka WatadaDepartment of Metabolism and Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Japan Diabetes Society (JDS) and the Japan Cancer Association (JCA) launched a joint committee and published their "First Joint Committee Report on Diabetes and Cancer" in 2013, compiling recommendations for physicians and healthcare providers as well as for the general population. In 2016, the "Second Joint Committee Report on Diabetes and Cancer" summarized the current evidence on glycemic control and cancer risk in patients with diabetes. The current "Third Joint Committee Report on Diabetes and Cancer", for which the joint committee also enlisted the assistance of the Japanese Society of Clinical Oncology (JSCO) and the Japanese Society of Medical Oncology (JSMO), reports on the results from the questionnaire survey, "Diabetes Management in Patients Receiving Cancer Therapy," which targeted oncologists responsible for cancer management and diabetologists in charge of glycemic control in cancer patients. The results of the current survey demonstrated that there is a general consensus among oncologists and diabetologists with regard to the need for guidelines on glycemic control goals, the relevance of glycemic control, and glycemic control during cancer therapy in cancer patients.

Indexed as

CancerDiabetesGlycemic controlQuestionnaire survey

Identifiers

PMID38264218
PMCPMC10800312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.